美股异动丨制药公司Aridis盘前涨超32% 公司获批在欧洲进行肺炎治疗的3期研究

Changes in US stocks | Pharmaceutical company Aridis rose more than 32% in the pre-market period, and the company was approved to conduct a phase 3 study on pneumonia treatment in Europe

Gelonghui Finance ·  07/18/2023 16:26

On July 18, | Pharmaceutical company Aridis Pharmaceuticals rose more than 32% before the market to $0.3490. According to the news, the all-human IgG1 monoclonal antibody (mAB) AR-301 developed by the company reached an agreement to conduct a phase 3 study on pneumonia treatment in Europe. AR-301 specifically targets Staphylococcus aureus alpha-toxin, which is related to the pathogenesis of pneumonia caused by Staphylococcus aureus. Additionally, Aridis received positive feedback from the FDA on the company's proposed Ar-301 single confirmatory phase 3 study in May 2023.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment